Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 12
  • Start Date: January 31, 2021
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Search for trials
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 130
  • Start Date: December 14, 2020
A Phase 1b Study of Mivebresib Alone or in Combination With Ruxolitinib or Navitoclax in Subjects With Myelofibrosis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Other, Drug
  • Participants: 456
  • Start Date: October 2, 2020
Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia
Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Diagnostic Test
  • Participants: 140
  • Start Date: September 30, 2020
Complement Activation in the Lysosomal Storage Disorders
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 230
  • Start Date: September 29, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
Clinical Trial
  • Status: Not yet recruiting
  • Participants: 300
  • Start Date: September 2020
Hematological Anomalies in Children With Rasopathy
Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Diagnostic Test
  • Participants: 370
  • Start Date: August 31, 2020
Construction and Evaluation of the Early Identification for Oxaliplatin Induced Portal Hypertension
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Procedure
  • Participants: 25
  • Start Date: August 31, 2020
Construction and Evaluation of the Early Identification and Individualized Treatment for Oxaliplatin-induced Portal Hypertension
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 130
  • Start Date: August 19, 2020
A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis
Showing 1-12 of 37